What is tremfya used for?

What is tremfya used for?

Tremfya treats moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is also approved for active psoriatic arthritis in adults.

Tremfya is a monoclonal antibody that targets interleukin-23, a protein involved in inflammation.

Why is Tremfya prescribed more often for skin symptoms than for joint symptoms?

Tremfya showed stronger skin clearance results in clinical trials, so doctors often use it first for visible plaque psoriasis. Joint improvements appear slower and sometimes less consistent.

How does Tremfya differ from other IL-23 inhibitors like Skyrizi?

Tremfya requires injections every eight weeks after the first two starter doses, while Skyrizi uses a different dosing schedule. Both block the same pathway, but clinical data show slightly different response rates in head-to-head comparisons.

Can Tremfya be used in patients who failed TNF inhibitors?

Yes. Clinical studies included patients who had previously tried TNF inhibitors and failed them. Tremfya still delivered skin and joint improvements in those cases.

When does Tremfya patent expire?

Tremfya’s primary patent expires in 2031, with additional patents covering formulations and manufacturing that could extend protection through 2034.